This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Basic science
June 23, 2022
May 26, 2022
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
May 18, 2022
Gripping vignette of a fatal case of renocardiac pathologies. The stills from the (sadly non-contrast) CTA are most interesting.
April 19, 2022
Interesting manuscript on the immunology of coronary atheroma, with tanslational potential in therapies and prevention of ischaemic heart disease.
April 5, 2022
A brief but comprehensive editorial on nuances of the links between atrial fibrillation and heart failure, apropos a trial we have commented recently on, by the Johns Hopkins team that develops the calmodulin-dependent protein kinase II inhibitor molecules
March 30, 2022
Interesting case-control study on variations of aortovascular compliance
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
December 12, 2021
Interesting early work on the prognostic value in aortic disease of the cross-link component in the elastin.
November 1, 2021
An extremely useful and free-access update on a major vascular entity. The 'Areas of Uncertainty' is a particularly useful chapter, discussing the available technology and its current supra-renal limitations and the emerging solutions.
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.